CN103917554B - 用于改善重构后纯化的因子viii的稳定性的方法 - Google Patents

用于改善重构后纯化的因子viii的稳定性的方法 Download PDF

Info

Publication number
CN103917554B
CN103917554B CN201280051574.0A CN201280051574A CN103917554B CN 103917554 B CN103917554 B CN 103917554B CN 201280051574 A CN201280051574 A CN 201280051574A CN 103917554 B CN103917554 B CN 103917554B
Authority
CN
China
Prior art keywords
factor viii
fviii
domain
activity
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280051574.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103917554A (zh
Inventor
C·霍恩
S·措尔纳
H·梅茨纳
S·舒尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Ltd filed Critical CSL Ltd
Publication of CN103917554A publication Critical patent/CN103917554A/zh
Application granted granted Critical
Publication of CN103917554B publication Critical patent/CN103917554B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201280051574.0A 2011-10-18 2012-10-18 用于改善重构后纯化的因子viii的稳定性的方法 Active CN103917554B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161548601P 2011-10-18 2011-10-18
EP11185651.4 2011-10-18
US61/548,601 2011-10-18
EP11185651 2011-10-18
PCT/EP2012/070701 WO2013057219A1 (en) 2011-10-18 2012-10-18 Method for improving the stability of purified factor viii after reconstitution

Publications (2)

Publication Number Publication Date
CN103917554A CN103917554A (zh) 2014-07-09
CN103917554B true CN103917554B (zh) 2017-03-08

Family

ID=48140377

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280051574.0A Active CN103917554B (zh) 2011-10-18 2012-10-18 用于改善重构后纯化的因子viii的稳定性的方法

Country Status (9)

Country Link
US (5) US9394353B2 (enExample)
EP (1) EP2768853A1 (enExample)
JP (2) JP2014531910A (enExample)
KR (1) KR20140084208A (enExample)
CN (1) CN103917554B (enExample)
AU (1) AU2012318292B2 (enExample)
CA (1) CA2850579A1 (enExample)
HK (1) HK1198541A1 (enExample)
WO (1) WO2013057219A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103917554B (zh) 2011-10-18 2017-03-08 杰特有限公司 用于改善重构后纯化的因子viii的稳定性的方法
ES2926798T3 (es) * 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
CN106456720A (zh) * 2014-04-01 2017-02-22 爱德技术生物科学有限公司 在无钙作为赋形剂下因子viii的稳定性
US9907835B2 (en) * 2014-04-01 2018-03-06 Advanced Bioscience Farmacêutica LTDA Stable Factor VIII formulations with low sugar-glycine
DK3193911T5 (da) * 2014-07-25 2024-10-14 Csl Behring Gmbh Forbedrede faktor VII-præparater til brug ved behandling af hæmofili A
JP6516829B2 (ja) * 2014-08-04 2019-05-22 シーエスエル、リミテッド 第ｖｉｉｉ因子製剤
KR102219859B1 (ko) * 2016-06-24 2021-02-25 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물
JP6877469B2 (ja) 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
KR20200057051A (ko) 2017-09-27 2020-05-25 시질론 테라퓨틱스, 인크. 활성 세포를 포함하는 방법, 조성물 및 이식 가능한 요소
WO2019074886A1 (en) 2017-10-09 2019-04-18 Terumo Bct Biotechnologies, Llc LYOPHILIZATION CONTAINER AND METHOD OF USE
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
CN112203646A (zh) 2018-04-04 2021-01-08 西吉隆医疗股份有限公司 可植入颗粒和相关方法
CN117467019A (zh) * 2018-05-18 2024-01-30 郑州晟斯生物科技有限公司 改进的fviii融合蛋白及其应用
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
US11609042B2 (en) 2019-03-14 2023-03-21 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
EP4061942A4 (en) 2019-11-22 2023-12-20 Sigilon Therapeutics, Inc. MONOCLONAL CELL LINES EXPRESSING AN EXOGENEOUS SUBSTANCE AND THEIR USES
CN120659872A (zh) 2022-10-11 2025-09-16 西吉隆医疗股份有限公司 用于治疗疾病的经工程化的细胞和可植入元件
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
MX9203440A (es) 1985-04-12 1992-07-01 Genetics Inst Proteinas procoagulantes novedosas.
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
IL84168A0 (en) 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
JP2872255B2 (ja) 1987-01-30 1999-03-17 バイオジエン，インコーポレイティド ファクター▲ｖｉｉｉ▼の高収量生産法
EP0294910B1 (en) 1987-06-12 1996-09-11 Immuno Ag Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
PT1754718E (pt) 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
WO2000024759A1 (en) 1998-10-23 2000-05-04 The Trustees Of The University Of Pennsylvania Systemic delivery of gene products via skin
EP1194161B1 (en) 1999-07-13 2005-11-23 Biovitrum Ab Stable factor viii compositions
DK1266006T3 (da) 2000-03-22 2006-01-16 Octagene Gmbh Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
AU2002312660A1 (en) * 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
CA2450125A1 (en) 2001-06-15 2002-12-27 Andre C. Schuh Gene therapy for hemophilia a
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
SI1624891T2 (sl) 2003-05-06 2013-09-30 Biogen Idec Hemophilia Inc. Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
US20080070251A1 (en) 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
WO2008077616A1 (en) * 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
EP2411024A4 (en) * 2009-03-24 2013-02-27 Bayer Healthcare Llc Variants of factor viii and associated methods of use
EP2467166A2 (en) 2009-08-20 2012-06-27 CSL Behring GmbH Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
CN103917554B (zh) 2011-10-18 2017-03-08 杰特有限公司 用于改善重构后纯化的因子viii的稳定性的方法
US9534029B2 (en) 2012-10-03 2017-01-03 Csl Behring Ag Method of purifying proteins

Also Published As

Publication number Publication date
HK1198541A1 (en) 2015-05-15
US11510968B2 (en) 2022-11-29
US20190038722A1 (en) 2019-02-07
JP2017114889A (ja) 2017-06-29
AU2012318292B2 (en) 2015-08-20
WO2013057219A1 (en) 2013-04-25
US20140249086A1 (en) 2014-09-04
US10537616B2 (en) 2020-01-21
EP2768853A1 (en) 2014-08-27
US20200268854A1 (en) 2020-08-27
JP2014531910A (ja) 2014-12-04
KR20140084208A (ko) 2014-07-04
US10881717B2 (en) 2021-01-05
AU2012318292A1 (en) 2013-05-02
CA2850579A1 (en) 2013-04-25
US20210308229A1 (en) 2021-10-07
US9956269B2 (en) 2018-05-01
CN103917554A (zh) 2014-07-09
US9394353B2 (en) 2016-07-19
US20160367641A1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
US11510968B2 (en) Method for improving the stability of purified Factor VIII after reconstitution
US9107902B2 (en) Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
JP6250282B2 (ja) 出血性障害の治療および予防的治療における非静脈内投与のためのアルブミン融合凝固因子
EP3793588B1 (en) Methods of treating hemophilia a
KR20090102795A (ko) 연장된 생체내 반감기를 갖는 변형된 응고 인자
CN106687126A (zh) 因子viii制剂
JP6072810B2 (ja) 第ｖｉｉｉ因子の生物学的利用能を改善するための硫酸化グリコサミノグリカンの使用
TW202317178A (zh) 因子ⅷ嵌合蛋白的配製品及其用途
AU2015258240A1 (en) Method of improving the stability of purified factor viii after reconstitution
CN114929261A (zh) 凝血因子viii的皮下施用
HK40079628A (en) Subcutaneous administration of factor viii
HK40049026B (en) Methods of treating hemophilia a
HK40049026A (en) Methods of treating hemophilia a
KR20200019749A (ko) 혈우병의 예방적 치료를 위해 인자 ix 및 사람 알부민을 포함하는 융합 단백질에 대한 21-일 투여 용법 및 이의 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Vitoria Australia

Applicant after: Ztel company limited

Address before: Vitoria Australia

Applicant before: CSL Limited

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: CSL LIMITED TO: JETT LTD.

Free format text: CORRECT: ADDRESS; FROM:

C14 Grant of patent or utility model
GR01 Patent grant